Ensayos clínicos

8.676 ensayos encontrados

ReclutandoClinicalTrials.gov

International Rare Histiocytic Disorders Registry (IRHDR)

OBSERVATIONALInicio: 1 de oct de 2014ID: NCT02285582

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

INTERVENTIONALInicio: 20 de sept de 2022ID: NCT05519085

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment

INTERVENTIONALInicio: 29 de feb de 2024ID: NCT06241118

ReclutandoClinicalTrials.gov

Pivotal Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Normal Pressure Hydrocephalus

INTERVENTIONALInicio: 26 de nov de 2024ID: NCT06498960

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

INTERVENTIONALInicio: 8 de oct de 2025ID: NCT07140913

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery

INTERVENTIONALInicio: 24 de jun de 2024ID: NCT06393374

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer

INTERVENTIONALInicio: 10 de jun de 2025ID: NCT06340568

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis

INTERVENTIONALInicio: 10 de oct de 2024ID: NCT06516952

ReclutandoFase 3ClinicalTrials.gov

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD)

INTERVENTIONALInicio: 13 de sept de 2023ID: NCT05878717

ReclutandoFase 2ClinicalTrials.gov

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

INTERVENTIONALInicio: 23 de ene de 2015ID: NCT02140255

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma

INTERVENTIONALInicio: 25 de sept de 2024ID: NCT06525220

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

INTERVENTIONALInicio: 10 de jul de 2025ID: NCT07011732

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).

INTERVENTIONALInicio: 3 de ago de 2022ID: NCT05261399

ReclutandoFase 3ClinicalTrials.gov

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

INTERVENTIONALInicio: 31 de dic de 2025ID: NCT07221357

ReclutandoClinicalTrials.gov

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

OBSERVATIONALInicio: 1 de jul de 2022ID: NCT05646394

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

INTERVENTIONALInicio: 8 de ago de 2023ID: NCT05947851

ReclutandoFase 2ClinicalTrials.gov

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations

INTERVENTIONALInicio: 19 de feb de 2025ID: NCT06980805

ReclutandoFase 3ClinicalTrials.gov

Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)

INTERVENTIONALInicio: 15 de feb de 2022ID: NCT05263206

ReclutandoFase 4ClinicalTrials.gov

Digoxina After Acute Hearte Failure

INTERVENTIONALInicio: 16 de dic de 2025ID: NCT07321509

ReclutandoFase 3ClinicalTrials.gov

A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone Propionate/Albuterol Sulfate Combination Compared to Fluticasone Propionate, Albuterol Sulfate or Placebo Delivered by Multidose Dry Powder Inhaler in Participants 12 Years and Older With Asthma

INTERVENTIONALInicio: 12 de dic de 2024ID: NCT06664619